Synthetic Genomics
1
80M
1
0.06
- Areas of investment
Summary
Synthetic Genomics appeared to be the Corporate Investor, which was created in 2005. The main office of represented Corporate Investor is situated in the La Jolla. The venture was found in North America in United States.
The important activity for fund was in 2014. The fund is constantly included in less than 2 investment rounds annually. Deals in the range of 50 - 100 millions dollars are the general things for fund.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Moreover, a startup needs to be at the age of 1 and less years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Human Longevity. Among the most successful fund investment fields, there are Health Care, Genetics.
The current fund was established by David C. Kiernan, Hamilton Smith, J. Venter, Juan Enriquez.
The typical case for the fund is to invest in rounds with 7 participants. Despite the Synthetic Genomics, startups are often financed by Singularity University Ventures. The meaningful sponsors for the fund in investment in the same round are Threshold, Tan Thay, OS Fund. In the next rounds fund is usually obtained by Threshold, StartUp Health, OS Fund.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 0
- Rounds per year
- 0.06
- Investments by industry
- Health Care (1)
- Biotechnology (1)
- Health Diagnostics (1)
- Genetics (1)
- Investments by region
-
- United States (1)
- Peak activity year
- 2014
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 8
- Avg. valuation at time of investment
- 980M
- Group Appearance index
- 1.00
- Strategy success index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Human Longevity | 04 Mar 2014 | Biotechnology, Health Care, Health Diagnostics, Genetics | Early Stage Venture | 80M | United States, California, San Diego |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.